Intellia Therapeutics (NTLA) Non Operating Investment Income (2019 - 2026)
Intellia Therapeutics (NTLA) reported Non Operating Investment Income of -$904000.0 for Q1 2026, down 300.0% year-over-year from $452000.0 in Q1 2025, and down 134.81% quarter-over-quarter from -$385000.0 in Q4 2025.
Intellia Therapeutics (NTLA) Non Operating Investment Income (2019 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 8 years of Non Operating Investment Income data on file, last reported at -$904000.0 in Q1 2026.
- Non Operating Investment Income for Q1 2026 came in at -$904000.0, down 300.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 million (up 94.79% YoY), and the FY2024 annual result was -$32.6 million, down 995.87% from the prior year.
- Non Operating Investment Income eased to -$904000.0 in Q1 2026 per NTLA's latest filing, from -$385000.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $3.6 million in Q4 2023 and troughed at -$20.4 million in Q2 2024.
- A 5-year average of -$2.2 million and a median of -$904000.0 in 2026 frame the typical range for Non Operating Investment Income.
- On a YoY basis, Non Operating Investment Income climbed as much as 715.53% in 2022 and fell as far as 93100.0% in 2022.
- A 5-year view of Non Operating Investment Income shows it stood at $3.4 million in 2022, then increased by 5.91% to $3.6 million in 2023, then plunged by 184.79% to -$3.1 million in 2024, then soared by 87.51% to -$385000.0 in 2025, then slumped by 134.81% to -$904000.0 in 2026.
- Business Quant data shows NTLA's Non Operating Investment Income at -$904000.0 in Q1 2026, -$385000.0 in Q4 2025, and $337000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -904,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -904,000.00 |
| Mar 31, 2026 | -904,000.00 |
| Dec 31, 2025 | -385,000.00 |
| Dec 31, 2025 | -385,000.00 |
| Sep 30, 2025 | 337,000.00 |
| Sep 30, 2025 | 337,000.00 |
| Jun 30, 2025 | -404,000.00 |
| Jun 30, 2025 | -404,000.00 |
| Mar 31, 2025 | 452,000.00 |
| Mar 31, 2025 | 452,000.00 |
| Dec 31, 2024 | -3.08 Mn |
| Dec 31, 2024 | -3.08 Mn |
| Sep 30, 2024 | -3.06 Mn |
| Sep 30, 2024 | -3.06 Mn |
| Jun 30, 2024 | -20.35 Mn |
| Jun 30, 2024 | -20.35 Mn |
| Mar 31, 2024 | -6.07 Mn |
| Mar 31, 2024 | -6.07 Mn |
| Dec 31, 2023 | 3.64 Mn |
| Dec 31, 2023 | 3.64 Mn |